Previously, we reported germline DNA variants associated with risk of urinary bladder cancer (UBC) in Dutch and Icelandic subjects. Here we expanded the Icelandic sample set and tested the top 20 markers from the combined analysis in several European case-control sample sets, with a total of 4,739 cases and 45,549 controls. The T allele of rs798766 on 4p16.3 was found to associate with UBC (odds ratio = 1.24, P = 9.9 × 10 −12 ). rs798766 is located in an intron of TACC3, 70 kb from UBC is estimated to be the 9th most common cancer world wide and the 13th most common cause of death from cancer 1 . About 90% of UBCs arise in the urothelium, and clinical and molecular evidence suggests that the disease can develop along at least two distinct pathways. About half of all UBCs are low-grade tumors characterized by activating somatic mutations in FGFR3 (encoding fibroblast growth factor receptor 3) and by a favorable prognosis despite a high risk of local recurrence 2 . The other half of all UBCs present with high grade and/or high stage at diagnosis and progress to muscle invasion or metastases in up to 50% of cases.
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The previously reported variant on 3q28 was also among the top 20 markers, but those on 8q24.3 or 5p15.33 were not.
Of the top 20 markers, we previously attempted to replicate eight of them 5 . We proceeded to genotype the remaining 12 markers in at least five of nine additional UBC case-control sample sets from Italy, the UK, Spain, Sweden, Belgium, Germany, Eastern Europe and The Netherlands (Supplementary Tables 2 and 3). Of these 12 follow-up markers, one, rs798766 on chromosome 4p16.3 ( Table 1) , replicated in the combined follow-up groups (P = 8.5 × 10 −8 ) and reached genome-wide significance in the overall analysis of the discovery and follow-up groups (OR = 1.24, 95% CI 1.17-1.32, P = 9.9 × 10 −12 ). To further investigate the association signal, we imputed all HapMap CEU (phase II) SNPs in a 1-Mb region centered on rs798766 for the Icelandic and Dutch discovery samples. Although rs798766 is strongly correlated (r 2 > 0.8) with 20 other HapMap CEU SNPs in the region (Supplementary Table 4) , none of those SNPs showed stronger association with UBC than rs798766. After conditioning on rs798766 and taking into account the number of tests performed, no further SNPs were significantly associated with UBC. When we compared the full model to the multiplicative model, we could not reject the multiplicative model (combined P = 0.91). Relative to noncarriers, the ORs for heterozygous and homozygous carriers of the T risk allele were estimated to be 1.24 and 1.54, respectively. The estimated population attributable risk was 9%.
rs798766 is located in intron 5 of TACC3 (encoding transforming, acidic coiled-coil containing protein 3), a member of a family of TACC genes that play a role in regulating microtubule dynamics. TACC3 shares a linkage disequilibrium (LD) block with two other genes, TMEM129 (encoding transmembrane protein 129 isoform b) and SLBP (encoding stem-loop (histone) binding protein) (Fig. 1) . Neither TMEM129, SLBP nor TACC3 has been previously implicated in UBC. In the adjacent LD block, centromeric to TACC3 and 70 kb away from rs798766, is FGFR3, which encodes fibroblast growth factor receptor 3. This gene has a strong link with UBC, as activating somatic mutations in FGFR3 are the most common mutations in low-grade bladder tumors that do not invade the submucosa (stage Ta, grade G1 (TaG1)) 8, 9 , where they have been found in 84% of cases and in 74% of stage-Ta UBC tumors overall 10 . In TaG1 tumors, FGFR3 mutations are associated with an increased risk of local recurrence, and in Ta and T1 tumors overall, FGFR3 mutations are associated with a reduced risk of progression 11 . This strong link with a particular clinical behavior of UBC tumors prompted us to investigate whether the frequency of rs798766[T] differs between clinical subtypes of UBC. For nine of the sample sets, we had information on stage and grade at diagnosis, which we used to classify the UBC cases into those with a predicted 'low risk' of progression (tumors confined to the bladder mucosa and not poorly differentiated) or those with a predicted 'high risk' of progression (tumor invasion in or beyond the lamina propria or poorly differentiated) (see Online Methods). In the combined analysis, the frequency of rs798766[T] was significantly higher in cases with low risk of progression than in those with high risk of progression (combined OR = 1.17, P = 0.009; Supplementary Table 5) . By regressing on the age at diagnosis, we found that rs798766[T] associated significantly with a younger age at diagnosis of UBC (effect = −0.81 years per allele, P = 0.0036; Supplementary Table 6) .
Detailed clinical follow-up information was available for the Dutch subjects, allowing us to evaluate the effect of rs798766 on the observed risk of recurrence in 1,109 cases with non-muscle invasive bladder cancer. The risk of recurrence was higher among cases with one copy (hazard ratio (HR) = 1.20, P = 0.046) or two copies of rs798766[T] (HR = 1.12, P = 0.58) than in noncarriers of the allele (Supplementary Table 7 ). The rs798766[T] allelic HR was estimated to be 1.13 (P = 0.090). When stratified by the diagnostic criteria used to classify low or high risk of progression, a significant difference in risk of recurrence was observed based on rs798766 genotypes among cases with predicted low risk of progression (log-rank test, P = 0.044) ( Supplementary Fig. 1a and Supplementary Table 7) . The corresponding HR per allele among cases with low risk of progression was 1.23 (P = 0.019). No significant difference in risk of recurrence was observed based on rs798766 genotypes among cases with predicted high risk of progression (log-rank test: P = 0.882; Supplementary Fig. 1b) .
Because smoking is a strong risk factor for UBC and because variants in the sequence of the genome that affect smoking behavior have been previously identified, we tested whether rs798766[T] was associated with smoking behavior by using genotypes and information on smoking from Icelandic subjects (15,310 ever smokers and 6,077 never smokers) 12 . No association was seen between rs798766 and smoking initiation (P = 0.24) or smoking quantity as measured by number of cigarettes smoked per day (P = 0.57). To search for potential interactions between smoking and rs798766, we compared the frequency of rs798766 [T] in smokers and nonsmokers among UBC cases (2,505 ever smokers and 415 never smokers). We did not observe a significant difference between the two groups (combined All P values shown are two sided. Shown are the allelic ORs with P values based on the multiplicative model, the corresponding numbers of cases and controls (n) and the allelic frequencies (Freq) of variants in affected and control individuals (freq).
a Results presented for Iceland and for The Netherlands discovery group were individually adjusted by the method of genomic control (see Online Methods). b For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, whereas the OR and the P value were estimated using the Mantel-Haenszel model. P het , P value for heterogeneity. l e t t e r s OR = 1.15, 95% CI 0.95-1.40, P = 0.16). Notably, previous studies have shown that neither smoking nor occupational exposure to polycyclic aromatic hydrocarbons seem to influence either the frequency or the pattern of FGFR3 mutations 13, 14 .
To test if rs798766 was tagging a mutation in the coding or regulatory parts of TACC3 and FGFR3, we sequenced all the exons, flanking regions and promoters of both TACC3 and FGFR3 in 184 UBC cases and 184 controls. We identified ten missense variants that occurred more than twice: five in TACC3 and five in FGFR3 (Supplementary Table 8 ). The genotypes of these variants were imputed into 561 UBC cases and 35,684 controls genotyped in the Icelandic study group by using a method of long-range phasing and haplotyping 15, 16 . None of these variants showed a significant association with UBC in Iceland, and rs798766 remained significant after adjustment for each of the ten missense variants (all P < 0.005). Because rs798766 resides in a noncoding region, it is possible that it may be associated with differential expression of nearby genes. Although it would be feasible to assess expression in normal urothelial biopsies, these are currently not available in the large numbers that would be needed to detect small differences. We assessed FGFR3 expression in 27 low-passage normal human urothelial cell strains using quantitative real-time RT-PCR. No significant association between rs798766 and FGFR3 expression was detected. However, our previous experiments using cultured normal urothelial cells showed that levels of FGFR3 mRNA fall markedly when cells are placed in culture but rise again at confluence and with senescence 17 . Therefore, these cells may not be suitable to assess potential association between genotype and expression. We also examined 47 bladder-cancer cell lines and found no relationship between rs798766 genotype and FGFR3 expression or mutation status. However, all of these 47 lines were derived from muscle-invasive tumors, and currently, there are no cell lines available that are representative of the papillary noninvasive bladder tumor group that shows the strongest association with rs798766 genotype.
As we did not have expression data from normal urothelial tissue, we attempted to search for correlation between rs798766 and expression of neighboring genes measured in high-quality samples from normal (healthy) blood (n = 747) and adipose tissue (n = 606) 18 . First, we examined whether rs798766 is associated with expression of any of the 15 transcripts located in a 1-Mb window centered on rs798766 (Supplementary Table 9 ). In adipose tissue, we observed a significant correlation between rs798766[T] and increased expression of FGFR3, TACC3 and TMEM129 ( Fig. 2 and Supplementary Table 10 ). The expression of FGFR3 in adipose tissue was increased by an estimated 22.4% with each T allele carried, whereas the expression of TACC3 and TMEM129 were increased by an estimated 9.1% and 3.6%, respectively (Fig. 2) . Expression of TACC3 was also significantly associated with rs798766[T] in blood (P = 1.0 × 10 −11 ), but the expression of FGFR3 in blood was too low to be reliably measured. When compared to the other 449 variants (directly typed or imputed) in the 1-Mb region centered on rs798766, rs798766 showed the strongest association with FGFR3 expression in adipose tissue, whereas rs2236786 (r 2 with rs798766 in HapMap CEU = 1.00) had the strongest correlation with TACC3 expression (Supplementary Table 10 ).
We used immunohistochemistry (IHC) to assess the level of FGFR3 protein in Ta tumors, scoring the tumors as having low (score 0 or 1) or high (score 2 or 3) levels of FGFR3 (Supplementary Fig. 2 ) 19 , where MLR is the mean log 10 expression ratio and the average is taken over individuals with a particular genotype. Regression of the MLR values on the number of copies of the UBC risk variant rs798766 [T] shows that the expression of FGFR3 is increased by an estimated 22.4% with each T allele carried, whereas the expression of TACC3 is increased by an estimated 9.1% with each allele. The effect of age and sex is taken into account in the regression by including the variables age, sex and the interaction of age × sex among the explanatory variables.
l e t t e r s was 0.30 compared to 0.17 in those with low levels (OR 2.18, P = 0.073). When the correlation between the number of rs798766[T] alleles and IHC class (0, 1, 2 or 3) was tested, we observed an increase of 0.42 in protein score per copy of rs798766[T] (P = 0.026). Activating mutations in FGFR3 are present in about 30% of all bladder cancers 20 and have the highest frequency in Ta tumors (74%) 10 . To determine if there is an association between the risk variant and somatic mutation in FGFR3, we tested the frequency of rs798766 [T] in stage-Ta tumors with (n = 57) or without (n = 33) mutation in the gene (Supplementary Table 11) . The frequency of the T allele of rs798766 was significantly higher in Ta tumors with FGFR3 mutations (frequency = 0.31) than in those without (frequency = 0.14) (allelic OR = 2.81, 95% CI 1.21-6.51, P = 0.016).
In summary, we have discovered an association between rs798766[T] at the TACC3-FGFR3 locus and increased risk of UBC and UBC recurrence. The variant shows a stronger association with tumors that have a low risk of progression than with tumors that have a higher risk of progression. Notably, the variant also associates with increased expression of FGFR3 and TACC3 in adipose tissue and FGFR3 protein level and somatic mutations of the FGFR3 gene in Ta bladder tumors. Intriguingly, recent studies of UBC showed that some microRNAs that are commonly downregulated in low-risk tumors are negative regulators of FGFR3, and that the resulting upregulation of FGFR3 expression appears to precede mutations in the gene 21 . Our observations are compatible with this model. Thus, it can be speculated that increased expression of FGFR3, caused either by germline variation or by downregulation of microRNAs targeting FGFR3 RNA, may lead to carcinogenesis in at least two ways. First, increased production of FGFR3 protein may increase the rate of urothelial proliferation and thus facilitate the accumulation of mutations that contribute to UBC development. Second, increased transcription may increase the chance of mutation in the FGFR3 gene itself. Further work will be needed to elucidate the link between germline variation at the TACC3-FGFR3 locus and urinary bladder carcinogenesis.
METHODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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